January 13, 2022 10:43 AM EST
News Briefing

Eye dis­ease biotech rais­es $46.9M in Se­ries B; Jour­ney Med­ical Cor­po­ra­tion shells out $20M up­front for der­ma­tol­ogy fran­chise

Paul Schloesser

Associate Editor

ONL Ther­a­peu­tics — an Ann Ar­bor, MI biotech that got its ini­tial back­ing from No­var­tis in a 2017 Se­ries A for its lead can­di­date Fas …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times